Montelukast: Discovery, Development, Safety and Pharmacovigilance

An evidence-based review of cysteinyl-leukotriene antagonism, pivotal asthma and rhinitis trials, the 2020 FDA boxed warning, 2024 MHRA action, evolving observational evidence and product-specific safety assessment.

Take test

Montelukast: Discovery, Development, Safety and Pharmacovigilance

Montelukast is an orally administered cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist developed to suppress leukotriene-mediated airway inflammation and bronchoconstriction. Its discovery offered an oral, once-daily approach to asthma control and later allergic rhinitis, but its modern pharmacovigilance identity is defined in large part by neuropsychiatric safety concerns. A medicine that improves respiratory symptoms can still require a more restrictive benefit–risk decision when the treated condition is mild and alternatives exist. The US Food and Drug Administration (FDA) added a boxed warning in 2020; the UK Medicines and Healthcare products Regulatory Agency (MHRA) reinforced patient and prescriber communication in 2024 [1–4].

This article separates what the molecule does, what its trials demonstrated, what regulators have communicated and what can be inferred from individual safety reports. It also distinguishes a US boxed warning, a UK patient-information boxed presentation, and EU/UK SmPC adverse-reaction frequency categories: these are not interchangeable regulatory constructs.

Discovery: from leukotriene biology to MK-0476

Cysteinyl leukotrienes, including LTC4, LTD4 and LTE4, are lipid mediators produced from arachidonic acid through the 5-lipoxygenase pathway. They contribute to bronchoconstriction, mucus secretion, vascular permeability and inflammatory-cell recruitment. Identifying receptor-mediated actions of LTD4 created a rational target for an orally active antagonist rather than another bronchodilator that simply relaxes smooth muscle downstream [5,6].

The montelukast programme originated at Merck Frosst's Canadian research organisation, where medicinal chemistry built on quinoline-containing leads and leukotriene pharmacophore concepts. Robert N. Young's discovery account documents the evolution of the antagonist programme and the compound's development designation MK-0476. The original work was a multi-investigator discovery programme; the historical literature does not justify attributing the final medicine to a single inventor [5,6]. The medicinal-chemistry achievement was not merely receptor affinity: oral potency, duration of action, tolerability and formulation had to support a practical once-daily medicine.

The US originator brand Singulair received its first FDA approval in 1998. Development, marketing and subsequent generic entry should be distinguished from the current marketing-authorisation holder of a particular presentation. The assessed US DailyMed originator label identifies Organon LLC as the contact company; it does not imply that Organon discovered the molecule [1,2].

Mechanism: selective CysLT1 antagonism

Montelukast binds CysLT1 receptors and inhibits the physiological actions of cysteinyl leukotrienes, including leukotriene-induced bronchoconstriction. It is not a corticosteroid, a beta2-agonist, an antihistamine or a leukotriene-synthesis inhibitor. Blocking one receptor-mediated inflammatory pathway can reduce symptoms and some measures of airway responsiveness, but it does not replace the broad anti-inflammatory effects of inhaled corticosteroids in patients who require them [1,7–9].

A mechanistic distinction matters in clinical and safety review. Montelukast may be used as a controller or add-on medicine according to the locally authorised indication; it does not treat an acute asthma attack. A patient experiencing severe acute bronchospasm needs appropriate rescue treatment. Likewise, reducing or abruptly stopping an inhaled or systemic corticosteroid when montelukast is added can create disease-control and diagnostic problems. Neither improvement in symptoms nor an oral route establishes equivalent protection from exacerbations across treatment options.

Pharmacokinetics, formulations and interactions

Montelukast sodium is administered orally as film-coated tablets, chewable tablets or granules, depending on country and age. The assessed US label lists 10-mg tablets, 4- and 5-mg chewable tablets, and 4-mg granules [1]. Doses and instructions differ by indication, age and formulation; a case assessment should identify the exact product rather than assume that all presentations are interchangeable.

The 10-mg oral tablet reaches peak concentrations at approximately three hours in fasted adults; mean bioavailability is approximately 64%. Montelukast is highly protein-bound and extensively metabolised, with CYP2C8 a major contributor and smaller roles for CYP2C9 and CYP3A4 [1,3]. The relatively short plasma half-life does not contradict once-daily dosing because pharmacodynamic activity and clinical response are not determined by half-life alone.

Drug-interaction interpretation must be based on in-vivo evidence, not simply an enzyme list. The UK SmPC reports that phenobarbital reduces montelukast exposure by approximately 40%, whereas gemfibrozil increases exposure by approximately 4.4-fold; it does not recommend routine dose adjustment with gemfibrozil but advises awareness of adverse reactions. Itraconazole did not significantly change exposure in the cited clinical study. These findings should not be extrapolated automatically to every CYP inhibitor or inducer [3]. For suspected treatment failure or adverse effects, record concomitant medicines and their start dates.

Clinical development: what efficacy trials established

Placebo-controlled chronic-asthma studies

In a multicentre, randomised, double-blind trial published in 1998, Reiss and colleagues evaluated once-daily montelukast in patients aged 15 years and older with chronic asthma. Lung-function and symptom outcomes supported clinical activity versus placebo [7]. Such trials demonstrate efficacy under specified inclusion criteria; they cannot determine the comparative effectiveness of every modern controller regimen or the long-term incidence of rare neuropsychiatric outcomes.

Seasonal allergic rhinitis

In a 2002 randomised trial involving 1,302 participants, montelukast 10 mg, loratadine 10 mg and placebo were compared over two weeks during the spring allergy season. Montelukast and loratadine improved the prespecified daytime nasal symptom score compared with placebo. The study supports symptom efficacy, not the proposition that montelukast should be the preferred first-line treatment for mild rhinitis [8]. Subsequent regulatory risk–benefit decisions took account of safer alternatives and emerging postmarketing concerns, which short efficacy trials could not fully characterise.

Comparative trials in children: endpoint matters

MOSAIC compared oral montelukast with inhaled fluticasone over 12 months in children aged 6–14 years with mild persistent asthma. Montelukast met a noninferiority criterion for the proportion of rescue-free days; nevertheless, asthma attacks and systemic corticosteroid use were more frequent in the montelukast group, and several secondary outcomes favoured fluticasone [9]. The Pediatric Asthma Controller Trial (PACT) also found fluticasone monotherapy superior to montelukast for asthma-control days and other measures in the studied population [10].

These results illustrate why a single noninferiority endpoint cannot be rewritten as global therapeutic equivalence. Trial population, background treatment, rescue medication, exacerbations and lung-function endpoints must be considered together. The original trials also predate some later safety communications, so their consent, monitoring and event-capture practices cannot be assumed to match today's pharmacovigilance expectations.

Regulatory evolution and the neuropsychiatric safety signal

Montelukast's regulatory history is best understood as a series of decisions under changing evidence and benefit–risk contexts. Early approvals followed efficacy and conventional clinical safety assessment. As exposure broadened, postmarketing reports described sleep disturbance, agitation, aggression, anxiety, depression, hallucinations and suicidal thoughts or behaviour. A rare serious event can remain clinically important even when available observational data do not establish a consistent increase in population-level risk [1–4,11–13].

2008–2019: recognition, review and communication

The FDA issued communications about possible neuropsychiatric effects beginning in 2008 and strengthened label information over subsequent years. A 2019 European review prompted additional warnings, including very rare reports of stuttering (dysphemia) and obsessive-compulsive symptoms [2,11]. In the UK, MHRA's 2019 communication described reported sleep, mood and behavioural changes and highlighted delayed recognition in some cases. The report history is important: it prevents the misleading impression that the safety issue first emerged in 2020.

March 2020: FDA boxed warning and rhinitis restriction

On 4 March 2020, FDA announced a boxed warning for serious neuropsychiatric events with montelukast. The agency also advised reserving use for allergic rhinitis in patients who respond inadequately to or cannot tolerate alternative therapies. For asthma and exercise-induced bronchoconstriction, clinicians should weigh benefits against mental-health risks before prescribing. FDA required stronger patient-facing Medication Guide information [2].

The distinction between indications is deliberate. Allergic rhinitis often has effective alternatives, so the acceptable balance of benefit and harm differs from a patient whose asthma requires additional controller treatment. The boxed warning does not mean montelukast was withdrawn from the market or universally contraindicated in patients with a psychiatric history. It requires a considered treatment decision, counselling and vigilance.

FDA's review included spontaneous reports, the Sentinel claims study and other literature. The agency identified 82 reports of completed suicide associated with montelukast from approval through May 2019, but most lacked enough information for a meaningful causality assessment. This is a count of reports, not an incidence estimate or a count of deaths proven to be caused by the drug [2]. The Sentinel analysis did not find a statistically significant increase in hospital-treated depression or self-harm versus inhaled corticosteroids for its defined outcomes; FDA explicitly noted limitations of claims data and incomplete capture of events not leading to coded medical encounters [2].

April 2024: MHRA emphasis on communication

On 29 April 2024, MHRA reiterated the risk in all age groups, including children and adolescents, and described more prominent boxed wording in UK patient information. The UK action was a communication and labelling reinforcement; it was not the introduction of a US-style FDA boxed warning into UK law [4]. MHRA advised clinicians to discontinue montelukast for new or worsening neuropsychiatric symptoms and to report suspected adverse reactions. The message also emphasised that family members and caregivers may detect changes not recognised by the patient.

2025 evidence: observational uncertainty remains

A nationwide Swedish active-comparator cohort study, published online in January 2025, included 74,291 children aged 6–17 years. Comparing montelukast with long-acting beta-agonists, investigators estimated a weighted hazard ratio of 0.99 (95% CI 0.84–1.16) for a composite neuropsychiatric outcome. The study did not find evidence of an increased risk for that prespecified composite, but uncommon outcomes and symptoms that never result in recorded healthcare encounters may be incompletely captured [12].

A 2023 systematic review of 59 studies found inconsistent associations across outcome definitions and ages. Several observational studies did not show associations with suicide or diagnosis-coded depression, while evidence suggested possible associations with anxiety and sleep disorders in adults, particularly older adults [13]. These studies do not nullify the label warning; they help define what is and is not measurable with different study designs. A responsible article must not infer either that every reported neuropsychiatric event is drug-caused or that a null composite estimate proves every individual risk absent.

Clinical recognition and immediate safety response

The reported neuropsychiatric spectrum includes vivid dreams or nightmares, insomnia, sleepwalking, irritability, aggression, anxiety, depressed mood, hallucinations, confusion, attention or memory disturbances, obsessive-compulsive symptoms, stuttering and suicidal thinking or behaviour [1–4,11]. The symptom set is heterogeneous, so a single composite outcome can hide differences in severity, detectability and biological plausibility.

The assessed US label advises immediate discontinuation and prompt contact with a healthcare provider if new behavioural changes, neuropsychiatric symptoms or suicidal thoughts/behaviour occur. UK MHRA advice likewise calls for stopping treatment when new or worsening neuropsychiatric symptoms arise [1,4]. Suicidal thoughts, self-harm risk, psychosis or severe behavioural disturbance require urgent clinical assessment; pharmacovigilance follow-up must never delay appropriate care.

Events have been reported in people with and without pre-existing psychiatric disease and, in some cases, after stopping treatment. A useful clinical history therefore includes baseline mood and sleep, the date treatment started, any dose or formulation change, the symptom chronology, whether treatment was stopped, subsequent symptom course and psychiatric or other confounders. An event beginning after withdrawal is not automatically unrelated, but neither is it automatically caused by montelukast.

Other important safety topics

Eosinophilia, systemic vasculitis and corticosteroid changes

Product information describes rare cases of systemic eosinophilia and clinical features consistent with eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg–Strauss syndrome) among patients receiving asthma therapies, including montelukast. Some cases occurred around corticosteroid dose reduction or withdrawal. A causal association with leukotriene receptor antagonism has not been established [1,3]. Reviewers should distinguish the possibility of previously suppressed disease becoming clinically evident from a drug-related reaction.

A report suggesting EGPA requires more than an elevated eosinophil count. Relevant details include asthma history, systemic corticosteroid trajectory, eosinophil measurements, neuropathy, rash, pulmonary infiltrates, cardiac or renal involvement, biopsy findings and specialist diagnosis. An unconfirmed report should not be coded or described as proven vasculitis.

Hepatic, hypersensitivity and cutaneous events

Postmarketing labels include hypersensitivity reactions such as anaphylaxis and angioedema, hepatic enzyme elevations and hepatitis, and selected skin reactions [1,3]. A hepatic safety case needs baseline and serial ALT, AST, alkaline phosphatase and bilirubin, timing of exposure, alcohol history, viral or autoimmune investigations and competing medicines. Serious hypersensitivity requires documentation of airway, skin and haemodynamic features, treatment and outcome. Listedness is not equivalent to certainty of causation in a specific patient.

Acute asthma, corticosteroid substitution and aspirin sensitivity

Montelukast is not a rescue treatment for an acute attack. In aspirin-sensitive asthma, treatment does not remove the need to avoid aspirin or other non-steroidal anti-inflammatory drugs that trigger reactions [1,3]. An apparent adverse event after starting montelukast may instead be deterioration of undertreated asthma, incorrect rescue-medication use or a change in inhaled corticosteroid adherence. The distinction matters to medical review, avoidable harm and risk-minimisation effectiveness.

Listedness against named public product labels

A defensible listedness assessment starts with a specific authorised product and version, not an INN-wide assumption. The comparison below was checked on 26 October 2026 against (a) US Singulair montelukast sodium tablets, chewable tablets and oral granules, DailyMed set ID 482dcc92-b47f-4ea6-854a-f5ac2aea7842, label revised June 2021 and DailyMed record updated 30 April 2025; and (b) UK Montelukast 10 mg film-coated tablets, Dr. Reddy's Laboratories (UK), electronic Medicines Compendium (emc) SmPC updated 3 April 2024 [1,3]. The portal update date is not a claim that the underlying USPI was revised in 2025.

The UK is not an EU Member State. A separate Irish/EU product, Montelukast Viatris 10 mg film-coated tablets, is indexed on medicines.ie, with a document-history entry showing an SmPC update on 20 January 2025 [14]. The Irish portal identifies the product and revision but the full current PDF text was not independently retrievable for line-by-line comparison in this review. Accordingly, the table is a US-versus-UK comparison; it must not be represented as a completed EU-versus-US assessment. For EU cases, obtain the applicable national SmPC before concluding whether a term is listed.

USPI and UK SmPC comparison

Safety or scope question US Singulair, June 2021 USPI UK Dr. Reddy's 10-mg tablet, April 2024 SmPC
Neuropsychiatric warning Boxed warning and section 5.1; serious events including suicidal thinking/behaviour; stop treatment and contact a clinician for new symptoms. Section 4.4 warning and section 4.8 psychiatric ADR list; discontinue if neuropsychiatric symptoms occur. UK MHRA added prominent patient-leaflet warnings in 2024.
Neuropsychiatric reaction listing Section 6.2 explicitly lists postmarketing psychiatric events including nightmares, insomnia, aggression, hallucinations, stuttering, obsessive-compulsive symptoms and suicidality; no frequency estimate from voluntary reports. Section 4.8 lists dream abnormalities, insomnia, somnambulism, anxiety, agitation and depression as uncommon; attention or memory disturbance and tic as rare; hallucinations, suicidality, obsessive-compulsive symptoms and dysphemia as very rare.
Common trial reactions Section 6.1 gives population-specific trial observations; highlights include respiratory infections, headache, abdominal pain and diarrhoea. Section 4.8 gives trial and postmarketing tables with frequency categories; frequency categories must not be transplanted to the US label.
Other serious reactions Section 6.2 includes anaphylaxis, angioedema, hepatitis, Stevens–Johnson syndrome/toxic epidermal necrolysis and other postmarketing terms; section 5.5 discusses eosinophilic conditions. Section 4.8 includes anaphylaxis, angioedema, hepatitis and eosinophilic/vasculitic presentations, among others. The assessed UK section 4.8 does not name SJS/TEN; absence from this section alone does not establish absence from every other UK or EU product label.
Indications US label covers asthma from 12 months, exercise-induced bronchoconstriction from six years, and seasonal/perennial allergic rhinitis in specified paediatric ages; allergic rhinitis use is restricted to inadequate response/intolerance to alternatives. The assessed 10-mg tablet is an add-on for inadequately controlled mild-to-moderate persistent asthma, can relieve seasonal rhinitis in patients with asthma, and covers exercise-related bronchoconstriction prophylaxis. Its 10-mg presentation is for patients aged 15 years and older.
Population and formulation US label spans film-coated tablets, chewable tablets and granules; product-specific paediatric doses and excipient warnings apply. UK comparison concerns only the 10-mg film-coated tablet; it cannot establish 4-mg granule or chewable-tablet listedness.

The table deliberately distinguishes a warning from an adverse reaction listed in an adverse-reactions section. For example, the US neuropsychiatric risk is both highlighted in a boxed warning and included in section 6.2; the UK frequency categories appear in section 4.8, not as a claim that every individual reported event has a proven causal relationship [1,3]. A term listed in one label may be absent from another because of different product, jurisdiction, revision or evidence standards; differences should be documented rather than explained speculatively.

Public-label listedness is not company-core listedness or case-specific expectedness. See also listedness, expectedness and reference safety information. An EU individual case safety report (ICSR) may require assessment against the applicable reference safety information and legal reporting criteria, which are not determined merely by whether a term appears in a public US label. A medically serious event can be listed and still warrant reporting, follow-up or signal review. Conversely, the unavailable Irish full-text label is an evidence gap, not proof of an unlisted reaction.

Special populations and exposure context

Children and caregivers

Age-specific authorisations differ by country and formulation. Under the assessed USPI, asthma treatment is authorised from 12 months, exercise-induced bronchoconstriction prevention from six years, seasonal rhinitis from two years and perennial rhinitis from six months [1]. These are not blanket permissions for every presentation. A child's case should record weight, exact dose, chewable versus granule formulation, administration method, caregiver observations and school or sleep changes. Children may describe anxiety, nightmares or attention symptoms differently from adults; caregivers can supply a vital chronology without establishing causality.

The US label notes that 4-mg and 5-mg chewable tablets contain aspartame, a phenylalanine source, relevant to phenylketonuria [1]. A formulation-specific excipient concern is not an adverse reaction attributable to the active substance in all products.

Pregnancy and breastfeeding

The US label states that available pregnancy cohort data have not established a drug-associated risk of major birth defects, while acknowledging limitations; uncontrolled maternal asthma itself carries risks [1]. The assessed UK SmPC recommends use in pregnancy or breastfeeding only when clearly essential [3]. These are different label formulations, not contradictory proof of safety or harm. Human milk exposure is described in the US label; infant outcomes and milk-production effects remain areas of limited evidence. For pregnancy surveillance, document gestational timing, maternal disease control, co-medication, fetal and infant outcomes and follow-up without claiming a spontaneous-case incidence rate.

Hepatic disease, renal impairment and older adults

The UK SmPC states that no dose adjustment is needed for mild-to-moderate hepatic impairment or renal impairment, while severe hepatic impairment has not been adequately studied [3]. This does not eliminate the need to assess a suspected hepatic reaction clinically. For older adults, polypharmacy, baseline sleep disturbance and psychiatric illness may complicate attribution; the evidence does not justify inventing an age-specific neuropsychiatric incidence.

Medication errors and product-quality questions

Montelukast errors can arise from incorrect age-strength selection, duplicate daily doses, confusing granules with chewable tablets, failure to follow granule administration instructions, or using montelukast as an acute rescue medicine. A case should identify brand, country, formulation, dose, time, packaging, actual administration, symptoms and corrective action. If a patient uses two montelukast-containing products, identify the duplicate exposure before attributing new symptoms to a single product.

A medication error without an adverse reaction is not automatically an ICSR meeting all reporting criteria. It may still require internal safety, quality or medication-error handling under applicable procedures and jurisdictional requirements. A suspected product defect and an adverse event can require linked but distinct records, with lot traceability and follow-up.

Pharmacovigilance case assessment: reconstructing the clinical course

Illustrative case 1: nightmares and behaviour change in a child

Illustrative scenario, not an actual ICSR. A child starts montelukast for asthma and develops nightmares, irritability and school difficulties after several days. A parent reports that symptoms improve after stopping the medicine. The chronology supports consideration of a suspected adverse reaction but does not establish that montelukast caused all symptoms.

The first follow-up should establish the exact start and stop dates, dose, formulation, adherence, baseline sleep and behaviour, asthma control, intercurrent infection, school or family stressors, and any new medicines. Capture whether the prescriber was informed, whether urgent evaluation was needed and whether symptoms fully resolved. Rechallenge is not a routine investigation to establish causality, particularly where serious neuropsychiatric events are suspected. The safety reviewer should distinguish a documented dechallenge from a hypothetical causal mechanism.

Illustrative case 2: severe mood symptoms after discontinuation

Illustrative scenario. An adult stops montelukast after insomnia, then develops worsening depression and suicidal thoughts. The FDA warning describes events that can persist or emerge after treatment discontinuation [1,2]. Clinical care and immediate risk assessment take precedence over case processing. The PV narrative must retain both on-treatment and post-discontinuation chronology, baseline psychiatric history, co-medications, life events, other causes and the outcome of specialist evaluation.

Do not automatically classify the post-withdrawal onset as a withdrawal syndrome or as unrelated exposure. The record should preserve what is known, what is inferred and what remains uncertain.

Illustrative case 3: eosinophilia after steroid reduction

Illustrative scenario. A patient starts montelukast, reduces oral corticosteroids and subsequently develops eosinophilia, neuropathy and pulmonary infiltrates. The reviewer should investigate possible EGPA and whether corticosteroid reduction unmasked previously suppressed disease. Record the full treatment and symptom timeline, eosinophil counts, imaging, specialist conclusions and management. Labelling recognises the clinical association but does not establish a direct drug-causation pathway [1,3].

Signal detection, benefit–risk review and risk minimisation

The montelukast experience illustrates a core distinction between signal detection and causal quantification. Spontaneous reports are valuable for unusual phenotypes, severity, chronology and new symptom clusters, but reporting is influenced by publicity, duplicate submissions, differing recognition and missing denominators. Claims-based studies can provide comparator estimates but may miss events managed without a coded consultation. Randomised trials can compare defined endpoints but are often too short or small for rare delayed outcomes. These evidence streams should be interpreted together rather than ranked by a single headline result [2,12,13].

A signal-review plan can stratify reports by age, indication, psychiatric history, symptom phenotype, formulation, time to onset and outcome. For suicidality, distinguish ideation, attempt and completed suicide; for sleep effects, distinguish nightmares, insomnia and parasomnias. Assess dechallenge cautiously and avoid treating an absence of rechallenge as a missing quality requirement. Duplicate detection and narrative follow-up matter especially when one event is reported by a clinician, caregiver and public channel.

Risk minimisation should be assessed for effectiveness, not merely whether a warning exists. A sponsor or health system may examine whether prescribers understand the rhinitis restriction, whether patients receive the current Medication Guide or local leaflet, whether caregivers know which symptoms warrant urgent review, and whether clinical systems support safe alternative treatment. These are examples of good operational practice, not claims that every regulator legally mandates these exact measures or indicators.

Safety question Useful evidence Decision or escalation
Is the event medically serious? Clinical presentation, treatment, hospitalisation, suicidal risk and outcome Urgent care and applicable expedited safety reporting
Is the exposure correctly attributed? Brand, strength, formulation, batch if available, start/stop dates, adherence Reconcile duplicate or incorrect exposure records
Is the event listed for the actual product? Dated USPI or national SmPC, relevant section, exact term and reference safety information Document listedness separately from case-specific expectedness
Is a new pattern emerging? Deduplicated cases, phenotype, chronology, comparator data, background rates Medical signal review and benefit–risk assessment
Is communication effective? Counselling evidence, patient-leaflet distribution, comprehension and follow-up Improve education and evaluate effectiveness

For EU operations, applicable legislation, GVP and the current reference safety information govern ICSR processing, signal management and periodic benefit–risk evaluation. Related QPPV references explain GVP Module IX signal management and risk-minimisation effectiveness evaluation. A local SOP should identify who reviews a serious neuropsychiatric case, who assesses aggregate signals, who owns label changes and how decisions are documented. Inspection-ready evidence includes source records, follow-up attempts, medical assessments, deduplication decisions, versioned labels, signal-review minutes, escalation records and evaluation of corrective actions. The purpose is traceability and a defensible decision, not a retrospective claim that every reported event was avoidable.

Practical review checklist

Key takeaways

Montelukast's development turned leukotriene-receptor pharmacology into a practical oral respiratory medicine. Its trials demonstrated efficacy in asthma and rhinitis, but comparative paediatric trials show why endpoint-specific noninferiority does not equal broad therapeutic equivalence. The FDA's 2020 boxed warning and MHRA's 2024 communication reflect the seriousness of reported neuropsychiatric events and the importance of alternative therapies, counselling and monitoring. Later observational studies refine uncertainty without erasing labelled warnings. Strong pharmacovigilance depends on product-specific listedness, careful clinical chronology, explicit uncertainty, appropriate reporting and demonstrable risk-minimisation effectiveness.

References

  1. US National Library of Medicine. DailyMed: Singulair (montelukast sodium), film-coated tablets, chewable tablets and oral granules. Set ID 482dcc92-b47f-4ea6-854a-f5ac2aea7842. USPI revised June 2021; DailyMed record updated 30 April 2025; accessed 26 October 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482dcc92-b47f-4ea6-854a-f5ac2aea7842
  2. US Food and Drug Administration. FDA requires Boxed Warning about serious mental health side effects for montelukast; advises restricting use for allergic rhinitis. Drug Safety Communication, 4 March 2020. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug
  3. Dr. Reddy's Laboratories (UK) Ltd. Montelukast 10 mg film-coated tablets: Summary of Product Characteristics. UK emc, last updated 3 April 2024; accessed 26 October 2026. https://www.medicines.org.uk/emc/product/3494/smpc
  4. Medicines and Healthcare products Regulatory Agency. Montelukast: reminder of the risk of neuropsychiatric reactions. Drug Safety Update, 29 April 2024. https://www.gov.uk/drug-safety-update/montelukast-reminder-of-the-risk-of-neuropsychiatric-reactions
  5. Young RN. Discovery of montelukast: a once-a-day oral antagonist of leukotriene D4 for the treatment of chronic asthma. Prog Med Chem. 2001;38:249–277. https://doi.org/10.1016/S0079-6468(08)70095-X
  6. Bernstein PR. Chemistry and structure–activity relationships of leukotriene receptor antagonists. Am J Respir Crit Care Med. 1998;157:S220–S226. https://doi.org/10.1164/ajrccm.157.6.mar-3
  7. Reiss TF, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med. 1998;158:1213–1220. https://doi.org/10.1001/archinte.158.11.1213
  8. Philip G, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32:1020–1028. https://doi.org/10.1046/j.1365-2222.2002.01422.x
  9. Garcia Garcia ML, et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics. 2005;116:360–369. https://doi.org/10.1542/peds.2004-1172
  10. Sorkness CA, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2007;119:64–72. https://doi.org/10.1016/j.jaci.2006.09.042
  11. Medicines and Healthcare products Regulatory Agency. Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions. Drug Safety Update, 19 September 2019. https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions
  12. Wintzell V, et al. Montelukast use and the risk of neuropsychiatric adverse events in children. JAMA Pediatr. Published online 21 January 2025. https://doi.org/10.1001/jamapediatrics.2024.5429
  13. Lo CWH, et al. Neuropsychiatric events associated with montelukast in patients with asthma: a systematic review. Eur Respir Rev. 2023;32:230079. https://doi.org/10.1183/16000617.0079-2023
  14. Medicines.ie. Montelukast Viatris 10 mg film-coated tablets: product document history. Irish SmPC update listed 20 January 2025; accessed 26 October 2026. Full revision text not independently verified. https://www.medicines.ie/medicines/montelukast-viatris-10-mg-film-coated-tablets-32933/doc-history

Regulatory Note

This is an educational, product-specific pharmacovigilance reference, not prescribing advice or a substitute for current locally authorised product information. US, UK and EU product labels differ in scope and regulatory terminology. The UK is not an EU Member State; this article does not claim to have verified the complete current Irish SmPC text. Spontaneous reports, comparative clinical trials, observational studies, label warnings, legal reporting duties and recommended operational practices are different evidence categories and must not be conflated.

Revision History

QPPV.com